VANCOUVER, Wash., Oct. 2, 2018 /PRNewswire/ — AbSci announced today the appointment of Andrew J.S. Jones, D. Phil. to AbSci’s Scientific Advisory Board. Dr. Jones currently serves on the Scientific Advisory Boards of Coherus Biosciences and ReForm Biologics.
“Dr. Jones brings over 35 years’ of experience to AbSci’s Scientific Advisory Board,” said Sean McClain, Founder and CEO of AbSci. “His extensive background in analytical characterization, particularly as the founding member of Genentech’s Medicinal and Analytical Chemistry department will be a valuable addition to our team.”
“It is rejuvenating to be working with a young and energetic company like AbSci. Their exciting technology not only has dramatic development, yield and production speed advantages for manufacture of complex biopharmaceuticals, it also guarantees 100% consistency in (lack of) glycosylation from batch to batch –allowing elimination of major analytical, development and validation costs when glycosylation is not required for product function. I look forward to the opportunity to help move the technology into the mainstream of biotech production options. “
About AbSci AbSci is a global leader in biomanufacturing technologies. The company’s SoluPro™ expression platform achieves ultra-high yields of soluble and active protein products and enables ultra-high efficiency purification processes. AbSci’s unique approach accelerates drug discovery timelines, increases manufacturing efficiencies, and drastically reduces costs for the biopharmaceutical industry. For more information, please visit www.absci.com.